Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Saenko, Daria V
NCT05216497: Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19	Completed	3	233	RoW	Ingavirin®, 90 mg capsules, Placebo	Valenta Pharm JSC	COVID-19	01/22	04/22
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a	Completed	3	407	Europe, Canada, US, RoW	Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir	Eiger BioPharmaceuticals	Hepatitis Delta Virus	10/22	03/23
MMH-407-009, NCT06263881: Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia	Recruiting	3	370	RoW	Raphamin, MMH-407, Placebo	Materia Medica Holding	Community-acquired Pneumonia, Pneumonia	12/26	12/26
NCT05364671: Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients	Active, not recruiting	3	813	RoW	Raphamin, Placebo	Materia Medica Holding	Coronavirus Disease 2019 (COVID-19)	12/24	12/24